Source:http://linkedlifedata.com/resource/pubmed/id/18425519
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2008-8-5
|
| pubmed:abstractText |
This study was an initial phase II trial in humans of molecular magnetic resonance (MR) imaging for improved visualization of thrombi in vessel territories potentially responsible for stroke using a new fibrin-specific contrast agent (EP-2104R). Eleven patients with thrombus in the left ventricle (n = 2), left or right atrium (n = 4), thoracic aorta (n = 4) or carotid artery (n = 1) as verified by an index examination (ultrasound, computed tomograpy, or conventional MR) were enrolled. All MR imaging was performed on 1.5 T whole-body MR-system using an inversion-recovery black-blood gradient-echo sequence. The same sequence was performed before and 2-6 h after low-dose intravenous administration of 4 mumol/kg EP-2104R. Two investigators assessed image quality and signal amplification. Furthermore, contrast-to-noise ratios (CNR) between the clot and the blood pool/surrounding soft tissue before and after administration of the contrast agent were compared using Student's t-test. MR imaging and data analysis were successfully completed in 10 patients. No major adverse effects occurred. On enhanced images, thrombi demonstrated high signal amplification, typically at the clot surface, with a significantly increased contrast in comparison to the surrounding blood pool and soft tissue (CNR for clot vs. blood pool, unenhanced and enhanced: 6 +/- 8 and 29 +/- 14; CNR for clot vs. soft tissue, unenhanced and enhanced: 0 +/- 4 and 21 +/- 13; P < 0.01 for both comparisons). EP-2104R allows for molecular MR imaging of thrombi potentially responsible for stroke. High contrast between thrombus and surrounding blood and soft tissues can be achieved with enhanced imaging.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Contrast Media,
http://linkedlifedata.com/resource/pubmed/chemical/EP-2104R,
http://linkedlifedata.com/resource/pubmed/chemical/Fibrin,
http://linkedlifedata.com/resource/pubmed/chemical/Gadolinium,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0938-7994
|
| pubmed:author |
pubmed-author:BotnarRene MRM,
pubmed-author:GüntherRolf WRW,
pubmed-author:GrahamPhil BPB,
pubmed-author:IbrahimTareqT,
pubmed-author:KatohMarcusM,
pubmed-author:KelleSebastianS,
pubmed-author:MaintzDavidD,
pubmed-author:NagelEikeE,
pubmed-author:OzgunMuratM,
pubmed-author:SpuentrupElmarE,
pubmed-author:VymazalJosefJ,
pubmed-author:WiethoffAndrea JAJ
|
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1995-2005
|
| pubmed:meshHeading |
pubmed-meshheading:18425519-Adult,
pubmed-meshheading:18425519-Aged,
pubmed-meshheading:18425519-Aged, 80 and over,
pubmed-meshheading:18425519-Contrast Media,
pubmed-meshheading:18425519-Female,
pubmed-meshheading:18425519-Fibrin,
pubmed-meshheading:18425519-Gadolinium,
pubmed-meshheading:18425519-Heart Diseases,
pubmed-meshheading:18425519-Humans,
pubmed-meshheading:18425519-Image Enhancement,
pubmed-meshheading:18425519-Magnetic Resonance Imaging,
pubmed-meshheading:18425519-Male,
pubmed-meshheading:18425519-Middle Aged,
pubmed-meshheading:18425519-Peptides,
pubmed-meshheading:18425519-Pilot Projects,
pubmed-meshheading:18425519-Reproducibility of Results,
pubmed-meshheading:18425519-Sensitivity and Specificity,
pubmed-meshheading:18425519-Stroke,
pubmed-meshheading:18425519-Thrombosis
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients.
|
| pubmed:affiliation |
Department of Diagnostic Radiology, University Hospital, Technical University (RWTH) Aachen, Aachen, Germany. spuenti@rad.rwth-aachen.de
|
| pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|